As aforementioned, GLP-1 RAs have gained popularity in the management of T2DM and obesity due to their efficacy in blood glucose regulation and weight management [12]. However, like any medication, GLP-1 RAs have side effects, predominantly GI in nature [8,13]. Liu et al. conducted a disproportionality study using the FDA Adverse Event Reporting System database (FAERS), analyzing 21,281 reports of GI toxicity [14]. The gene discussed is GLP1R; the disease is obesity disorder.